InFocus Capital Partners

InFocus Capital Partners specializes in the identification, capitalization, and development of breakthrough and disruptive opportunities in life sciences with an ophthalmic focus. The Fund's experience, partnership structure, and coverage of ophthalmic innovations yield a differentiated investment opportunity — optimizing the probability of successful returns. Founded in 2016 and headquartered in Jericho, New York, the venture capital firm was co-founded by board-certified ophthalmologists Ron Weiss, MD, and Robert Rothman, MD. Beyond capital, it draws on a deep advisory board of leading glaucoma, cornea, and retina specialists from institutions like Columbia and Northwell, alongside a strategic partnership with Ora, Inc. for deal flow and regulatory support. InFocus focuses exclusively on early-stage ophthalmology and ophthalmic life sciences companies, prioritizing disruptive potential, seasoned management, and attractive valuation. Notable investments include ONL Therapeutics, Trefoil Therapeutics, Pr3vent, Qura, Camras Vision, Alievio, and Galimedix. Typical deal sizes range from $5 million to $10 million, usually as part of syndicated rounds with three to four co-investors. Its investment approach leverages deep clinical domain expertise and a specialized ophthalmic network to source and diligence opportunities others may overlook.